XML 64 R54.htm IDEA: XBRL DOCUMENT v3.22.2.2
Share-Based Compensation - Summary of the Option Unit Activity (Details)
$ / shares in Units, $ in Millions
9 Months Ended
Sep. 30, 2022
USD ($)
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Expected weighted average period 3 years 1 month 6 days
2021 Equity Plan [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of units, grant outstanding beginning balance | shares 3,714,540
Number of units, granted | shares 608,122
Number of grants, forfeited | shares (11,000)
Number of units, grant outstanding ending balance | shares 4,311,662
Number of grants, vested | shares 1,004,552
Number of grants, unvested | shares 3,307,110
Weighted average exercise price, grant outstanding beginning balance | $ / shares $ 15.33
Weighted average exercise price, exercised | $ / shares 14.68
Weighted average exercise price, forefeited | $ / shares 17.52
Weighted average exercise price, grant outstanding ending balance | $ / shares 15.24
Weighted average exercise price, grants vested | $ / shares 15.08
Weighted average exercise price, grants unvested | $ / shares $ 15.28
Weighted Average Remaining Contractual Term, grants outstanding 8 years 10 months 24 days
Expected weighted average period 8 years 8 months 12 days
Aggregate Intrinsic Value, grants outstanding | $ $ 0.0
Aggregate Intrinsic Value, grants vested | $ $ 0.0
First Advantage Corporation [Member]  
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]  
Number of units, grant outstanding beginning balance | shares 3,519,563
Number of grants, exercised | shares (309,087)
Number of grants, forfeited | shares (315,865)
Number of units, grant outstanding ending balance | shares 2,894,611
Number of grants, vested | shares 707,264
Number of grants, unvested | shares 2,187,347
Weighted average exercise price, grant outstanding beginning balance | $ / shares $ 6.66
Weighted average exercise price, exercised | $ / shares 6.65
Weighted average exercise price, forefeited | $ / shares 6.61
Weighted average exercise price, grant outstanding ending balance | $ / shares 6.66
Weighted average exercise price, grants vested | $ / shares 6.64
Weighted average exercise price, grants unvested | $ / shares $ 6.67
Weighted Average Remaining Contractual Term, grants outstanding 7 years 3 months 18 days
Expected weighted average period 7 years
Aggregate Intrinsic Value, grants outstanding | $ $ 17.8
Aggregate Intrinsic Value, grants vested | $ $ 4.4